Benitec Biopharma Cash on Hand 2014-2022 | BNTC

Benitec Biopharma cash on hand from 2014 to 2022. Cash on hand can be defined as cash deposits at financial institutions that can immediately be withdrawn at any time, and investments maturing in one year or less that are highly liquid and therefore regarded as cash equivalents and reported with or near cash line items.
Benitec Biopharma Annual Cash on Hand
(Millions of US $)
2021 $20
2020 $10
2019 $16
2018 $12
2017 $13
2016 $13
2015 $18
2014 $29
2013 $2
Benitec Biopharma Quarterly Cash on Hand
(Millions of US $)
2022-03-31 $9
2021-12-31 $12
2021-09-30 $16
2021-06-30 $20
2021-03-31 $12
2020-12-31 $14
2020-09-30 $7
2020-06-30 $10
2020-03-31
2019-09-30
2017-09-30 $12
2016-09-30 $10
2016-06-30 $13
2016-03-31 $14
2015-12-31 $16
2015-06-30 $18
2014-12-31 $23
2014-06-30 $29
2013-06-30 $2
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.007B $0.000B
Benitec Biopharma Limited is a biotechnology company which developed a patented gene silencing technology delivered by gene therapy called DNA directed RNA interference. The company is developing ddRNAi-based therapeutics for chronic and life-threatening human conditions including hepatitis C and B, drug resistant lung cancer and wet age-related macular degeneration. Benitec Biopharma Limited is based in Sydney, Australia.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $160.059B 9.71
GSK (GSK) United Kingdom $81.408B 9.78
Bio-Rad Laboratories (BIO.B) United States $15.412B 34.05
QIAGEN (QGEN) Netherlands $11.018B 18.45
Biohaven Pharmaceutical Holding (BHVN) United States $10.535B 0.00
Ginkgo Bioworks Holdings (DNA) United States $5.561B 0.00
Arcus Biosciences (RCUS) United States $1.821B 35.53
Myovant Sciences (MYOV) United Kingdom $1.600B 0.00
Emergent Biosolutions (EBS) United States $1.482B 8.59
Zymeworks (ZYME) Canada $0.390B 0.00
Enzo Biochem (ENZ) United States $0.120B 0.00
Gelesis Holdings (GLS) United States $0.104B 0.00
SQZ Biotechnologies (SQZ) United States $0.097B 0.00
Ambrx Biopharma (AMAM) United States $0.089B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00